With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.258515-65-0,tert-Butyl 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate,as a common compound, the synthetic route is as follows.
V.5. a 7-lodo-3,4-dihydro-1 /-/-isoquinoline-2-carboxylic acid te/f-butyl esterTo a mixture of 55,8 g (0,179 mol) 7-Bromo-3,4-dihydro-1 /-/-isoquinoline-2-carboxylic acid te/f-butyl ester in 180 ml Dioxan are added 3,473 g (17,87 mmol) copper (I) iodide, 53,58 g (357,41 mmol) sodium iodide and 3,806 ml (35,74 mmol) N, N’- Dimethylethylenediamine. The reaction mixture is refluxed for 18 hours. 300 ml of 5% aqueous ammonia solution are added and the mixture is extracted two times with ethyl acetate. The combined organic extracts are extracted with aqueous ammonia solution and then water. The organic phases are dried over magnesium sulphate and concentrated to dryness. The residue is washed with petrol ether. Yield: 35,4 g (55% of theory),EII mass spectrum: m/z = 360 [M+H]+, 258515-65-0
258515-65-0 tert-Butyl 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate 15885175, aisoquinoline compound, is more and more widely used in various fields.
Reference:
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GmbH; BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG; WO2008/71646; (2008); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem